KLOW
KLOW is a combination of four peptides sold as one vial: GHK-Cu, KPV, BPC-157 and TB-500. It is discussed in research on tissue repair, gut, skin and recovery, though no published study has tested the four together.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- BPC-157 / GHK-Cu / TB-500 / KPV, BPC-157 10mg / GHK-Cu 50mg / TB-500 10mg /KPV 10mg 80mg
- Recovery & tissue repair
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. All 2 sources
- 80 mg in 3 mL
How much to draw
Full calculator →The reference does not report a single injectable amount for KLOW, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for KLOW or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| ~6.0 mg total blend per day (22.5 units / 0.225 mL at 3.0 mL reconstitution) at maintenance phase; titration starts at ~2.0 mg total blend (7.5 units) and steps up to ~4.0 mg (15 units) then ~6.0 mg (22.5 units) | Once dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4 weeks off; Maximum extension: up to 16 weeks on, 4+ weeks off (no safety data supports continuous use beyond 12 weeks) | subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
| Commonly, a once-daily subcutaneous injection is used, with a typical cycle of 4-6 weeks on and 2-4 weeks off. | not stated | not stated | Peptide Dosing Protocols stack |
- Once dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4 weeks off; Maximum extension: up to 16 weeks on, 4+ weeks off (no safety data supports continuous use beyond 12 weeks)
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- not stated
- not stated
- Peptide Dosing Protocols stack
- Add 3.0 mL bacteriostatic water to the 80 mg vial to yield ~26.7 mg/mL total blend concentration. Steps: (1) Inspect the vial, check label, batch, and powder appearance; a discolored or damp vial should not be used. (2) Sanitize, swab the rubber stopper of the KLOW vial and the bacteriostatic water vial with alcohol prep pads and let dry. (3) Draw 3.0 mL bacteriostatic water with a sterile syringe; vent the BAC water vial if needed. (4) Inject down the vial wall, insert the needle and inject BAC water slowly down the inside wall; avoid spraying directly onto the powder to prevent foaming and denaturation. (5) Swirl, do not shake, gently swirl or roll until powder is fully dissolved; solution should be clear with possible light blue tint from GHK-Cu (normal). (6) Label with reconstitution date and store at 35.6-46.4°F (2-8°C), protected from light. (7) Use within 14-28 days when refrigerated; avoid freeze-thaw cycles.
- Add 3.0 mL of bacteriostatic water to the 80 mg vial.
We have not published an audit on KLOW. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Each of the four parts has its own research record: GHK-Cu for skin and connective tissue, KPV as an anti-inflammatory fragment, BPC-157 for soft-tissue repair, and TB-500 for cell migration and wound healing. Researchers link KPV to blocking NF-kB activation in intestinal cells through PepT1-mediated transport, GHK-Cu to changes across more than 4,000 human genes with more collagen and elastin in animal and skin studies, and both BPC-157 and TB-500 to angiogenesis, the growth of new blood vessels, in animal models. The standard vial holds 80 mg in total, 50 mg of GHK-Cu and 10 mg each of KPV, BPC-157 and TB-500. No published study has tested whether the four work together, against each other, or how they interact in the body.
Adds KPV (anti-inflammatory) to the GHK-Cu/BPC-157/TB-500 repair blend; studied for tissue repair, gut, skin, and recovery.
Reported side effects
Reported by users: mild redness, swelling or sensitivity where it is injected, and sometimes a faint blue-green tint at the site, which is linked to the copper in GHK-Cu and is cosmetic only. Mild fatigue in the first week and short-lived digestive changes are also commonly described, with less frequent reports of headache, light-headedness, vivid dreams often attributed to BPC-157, and brief appetite changes.
Not ruled out: there are no published safety studies of the four-peptide combination. Copper can build up with prolonged continuous use because of the GHK-Cu, BPC-157 and TB-500 promote new blood vessel growth, which matters for anyone with active or recent cancer, interactions between the four in the body are unknown, and quality varies between research-use suppliers. Sources say pronounced symptoms such as significant swelling, ongoing dizziness, rapid heart rate, shortness of breath or marked fatigue are a reason to stop and seek qualified medical care.
Who should avoid it
People with active or recent cancer: BPC-157 and TB-500 promote the growth of new blood vessels.
People with Wilson's disease or other copper metabolism disorders: the GHK-Cu component carries copper.
People who are pregnant or breastfeeding: there is no safety data for any of the four components.
Competitive athletes in WADA-tested sport: BPC-157 and TB-500 are listed under WADA category S0, unapproved substances.
People taking anticoagulants: sources advise particular caution because of the components that promote blood vessel growth.
What gets monitored
CBC with differential (baseline); Comprehensive metabolic panel (CMP) (baseline); CRP (follow-up); ESR (optional); Copper and ceruloplasmin (optional, for repeated high-exposure GHK-Cu use). (reported by peptidedosingprotocols.com)
Common questions
What is the KLOW peptide blend?
KLOW is a research-context name for a four-peptide blend of GHK-Cu, KPV, BPC-157 and TB-500 in one vial. The standard format is an 80 mg vial holding 50 mg GHK-Cu and 10 mg each of the other three. It is not an FDA-approved treatment, and no published clinical trial has tested the four together.
What does KLOW peptide blend research focus on?
Community discussion centres on tissue repair, skin and connective-tissue remodelling, recovery, and anti-inflammatory research. These are research-context interests rather than validated clinical outcomes, and direct human evidence for the combination does not exist.
How is the KLOW peptide blend dosed in research planning?
Reported amounts and schedules for KLOW differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is the difference between KLOW and GLOW peptides?
GLOW is a three-peptide blend of GHK-Cu, BPC-157 and TB-500, while KLOW adds KPV as a fourth. KPV is what sets KLOW apart, and its research focus is anti-inflammatory signalling through NF-kB inhibition and PepT1-mediated transport in gut models. Sources describe KLOW as the more common choice when chronic inflammation is part of the research interest.
How long is a typical KLOW cycle?
Community-derived cycle structures most often run 4 to 6 weeks on followed by 2 to 4 weeks off, and some extend to 8 to 12 weeks with longer breaks. The stated reason for the off period is concern about copper building up from GHK-Cu, which makes up 62.5% of the blend.
How is the KLOW peptide blend reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is the KLOW peptide blend FDA-approved?
No. As of June 2026 none of the four peptides are FDA-approved for the uses discussed in the research community. BPC-157 and TB-500 are also listed by WADA under category S0, unapproved substances, and are prohibited in tested sport.
Who should avoid the KLOW peptide blend?
Contraindications cited in the research-use community include anyone with active or recent cancer, because BPC-157 and TB-500 promote new blood vessel growth, people with Wilson's disease or other copper-metabolism disorders because of GHK-Cu, anyone pregnant or breastfeeding given the absence of safety data, and athletes subject to WADA testing.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.
LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
Thymosin Alpha-1 (TA1) is a lab-made copy of a 28-amino-acid peptide that the thymus gland makes naturally. It is studied mostly in people as an immune treatment, and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on in cancer care.